ImmunotherapyMicrosatellite instabilityMismatch repair deficiencyColorectal cancers (CRCs) with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) often have sustained responses to immune checkpoint inhibitors (ICIs) including selective monoclonal antibodies against Program Death 1 (PD-...
Multiple avenues are being explored to predict outcomes for immunotherapy so physicians can select the best treatment for their patients, including the use of molecular biomarkers. The mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) biomarker, which is found ...
Cancer immunotherapy Prevention Abbreviations CMMRD constitutional mismatch repair deficiency COX cyclooxygenase CRC colorectal cancer CTLs cytotoxic T lymphocytes GBM glioblastoma multiforme LS Lynch syndrome MMR mismatch repair MSI microsatellite instability Tregs regulatory T cells ...
Treatment strategies for DNA repair-deficient prostate cancer In addition, tumors with mismatch repair defects (i.e. microsatellite instability) may be particularly susceptible to checkpoint blockade immunotherapy. Expert ... BA Teply,ES Antonarakis - 《Expert Review of Clinical Pharmacology》 被引量:...
Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The hypermutator-phenotype of dMMR tumours theoretically enables high evolvability but their evolution has not been investigated. Here we...
Mismatch repair-deficient endometrial cancers have a high somatic mutation burden, suggesting that patients with these tumors may benefit from immunotherapy. Elucidating the immune suppressive mechanisms of mismatch repair-deficient endometrial cancers is fundamental to developing future immune-based ...
Mismatch repair deficiency (dMMR) occurs when the proteins that repair mismatch errors in DNA replication are missing or non-functional, leading to microsatellite instability-high (MSI-H) tumors. Approximately 5-7% of metastatic CRC patients have dMMR or MSI-H tumors. These patients are less lik...
Mismatch repair deficiency (MMRD) is a common pathway of malignant transformation accounting for approximately 15鈥 20% of human carcinogensis. It has been ... MP Castro,N Goldstein - 《Journal for Immunotherapy of Cancer》 被引量: 7发表: 2015年 DNA Mismatch Repair in Cancer Mismatch repairIm...
Mismatch repair deficiency in histologically classifiable sarcomas is rare (1%) and is more common in unclassified sarcomas (10%). Additional study is required to determine the predictive role of mismatch repair-deficiency in sarcomas for immunotherapy. 展开 ...
Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science. 2019;364(6439):485–91. Article CAS PubMed PubMed Central Google Scholar Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin ...